ClinicalTrials.gg
RecruitingNCT04409340VisCanUpdated Sep 17, 2026

Viscoelasticity Imaging to Assess Liver Cancer

An observational study in Liver Cancer, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Observational

How we know

From the registry’s dates

  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Liver Neoplasms with a site in Canada — 13 open to participants now, 22 under way, 3 of them phase 3. Liver Neoplasms · Canada.

Planned enrollment
8th of 13
200 · median 328
Started
2020
with 3 others
Observational
13 of 70
7 open now
Primary completion
2027-10
later than 16 of 21 live
Registered
55th of 70
by date
Lead sponsor
2 of 70
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 70 studies in Liver Neoplasms with a site in Canada, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2020, is one of 13 observational ones, reaches primary completion later than 16 of the 21 other live ones, and was the 55th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

13 of the 70 studies in Liver Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Liver Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

Ultrasound (US) used for hepatocellular carcinoma (HCC) surveillance suffers from low sensitivity (60-78%) due to fatty liver, obesity, and diffusely nodular appearance in cirrhosis. Once a suspicious malignant lesion is detected at US, guidelines recommend contrast-enhanced US, magnetic resonance imaging (MRI) or computed tomography (CT) scans to confirm suspicion. The investigators' team has developed innovative quantitative US (QUS) techniques that have a high potential to improve tissue characterization in terms of sensitivity and specificity. The investigators hypothesize that advanced QUS providing tumor viscoelasticity assessment, sub-resolution tissue structure characterization and US attenuation in the framework of a machine learning classification model can improve HCC diagnosis compared with standard US.

Early detection through systematic US surveillance translates into curative therapy in a higher proportion of patients and into improvements in survival rates. Thus, there is an urgent need to investigate innovative and cost-effective imaging techniques for improving detection and characterization of HCC. The proposed QUS methods are experimental and will be validated in this proof-of-concept clinical study. A major impact of this work, for patients and medical institutions, will be to improve early-stage detection and characterization of HCC, and offer alternatives in patients with negative or inconclusive conventional US. QUS are low-cost, non-invasive and non-irradiating imaging modalities available from a single exam (i.e., no additional imaging session is necessary).

Read the detailed description

RESEARCH QUESTION AND BACKGROUND: Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women and is the second cause of cancer mortality worldwide. In Canada, HCC is the only cancer for which mortality is increasing. More than 80% of HCC cases occur in individuals with advanced liver fibrosis (cirrhosis) due to viral hepatitis infection (B and C), non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. Once cirrhosis is established, there is a significantly increased risk of developing HCC. Furthermore, HCC is observed in obese diabetic individuals without cirrhosis, increasing the population of patients at risk with a disease that has high fatality rate. HCC surveillance is associated with significantly prolonged survival. However, only 52% of patients undergoing surveillance have early HCCs that are eligible for curative treatment, whereas remainder of patients have intermediate- or advanced-stage disease eligible for bridge or palliative treatment only. HCC surveillance is also associated with significant improvements in early-stage detection, curative-treatment rates, and survival, even after adjusting for lead-time bias. North American guidelines recommend ultrasound (US) surveillance every 6 months in at-risk patients who are non-cirrhotic hepatitis B carriers and cirrhotic. However, a key challenge for US is the low sensitivity (60-78%) for identifying a lesion due to liver steatosis and cirrhosis. Once a suspicious malignant lesion is detected at US, current American Association for the Study of Liver Diseases (AASLD) guidelines recommend contrast-enhanced US, magnetic resonance imaging (MRI) or computed tomography (CT) scans to confirm suspicion.

GOAL: The long-term reaching goal is to develop US biomarkers of focal liver lesions and strategies to improve diagnostic sensitivity to HCC while maintaining a high specificity. This would constitute a major breakthrough because HCC diagnosis currently requires a combination of US for screening and confirmation using MRI, CT and less often biopsy.

OBJECTIVES: 1) Develop a machine learning model based on QUS for classification of solid hepatocellular carcinomas identified at US and diagnosed with MRI (or biopsy if required); 2) Determine if QUS maps can improve visual detection of suspected lesions at US; 3) Compare performance of QUS- versus MRI-based viscoelastography for lesion characterization.

Hypothesis: the investigators hypothesize that advanced QUS providing tumor viscoelasticity assessment, sub-resolution tissue structure characterization and US attenuation in the framework of a machine learning classification model can improve HCC diagnosis compared with standard US.

METHODOLOGY - Study design: This will be a clinical study with two sequential cohorts: 1) a training cohort of 100 patients at risk for HCC to optimize QUS biomarkers for classification of solid liver lesions using MRI and/or biopsy as gold standard clinical references; and 2) a validation cohort of 100 patients to confirm diagnostic performance.

Data analysis: Random forests machine learning to develop QUS classification models. Sensitivity and specificity to assess diagnostic accuracy, according to MRI and/or biopsy, with bootstrapping to obtain confidence intervals with training set. Confirmation of accuracy on test set. Inter-observer assessment of lesion detectability on clinical B-mode US versus QUS maps. Comparison of US- and MRI-based elasticity and viscosity according to diagnostic results.

03

Conditions studied

  • Liver Cancer

Browse trials for

Keywords

  • quantitative ultrasound
  • Viscoelasticity
  • Homodyned-K imaging
  • Liver cancer
  • Viscoelastography
  • Ultrasound attenuation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigators propose a cross-sectional prospective clinical study with two sequential cohorts: 1) a training cohort of 100 patients at risk for HCC to optimize QUS biomarkers for classification of solid liver lesions using MRI and/or biopsy as gold standard clinical references; and 2) a validation cohort of 100 patients to confirm diagnostic performance. The investigators will recruit patients seen at the hepatology clinic of the University of Montreal Hospital (CHUM).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are at least 18 years old at screening;
  • Able to comprehend and willingness to provide voluntary consent;
  • Are able to have a MRI;
  • Understand French or English;
  • Patients enrolled in a monitoring program or referred for the characterization of a focal liver lesion;
  • Focal liver lesion is visible during ultrasound screening in B-mode.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or trying to become pregnant;
  • Have a weight or girth preventing from entering the MR magnet bore;
  • Are unable to understand or unwilling to provide written for this study;
  • Have a to MRI (pacemaker, insurmountable claustrophobia);
  • Have chronic kidney disease preventing the injection of gadolinium-based contrast agent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Training cohort

    All patients enrolled will undergo: * Magnetic Resonance Viscoelastography * Quantitative ultrasound (QUS)

    Device: Magnetic Resonance Viscoelastography · Device: QUS

  • Validation cohort

    All patients enrolled will undergo: • Quantitative ultrasound (QUS)

    Device: QUS

Interventions

  • DeviceMagnetic Resonance Viscoelastography

    Magnetic Resonance Viscoelastography

  • DeviceQUS

    QUS

06

What researchers measure

Primary outcomes

  1. Liver viscoelastography determined by MRI

    Measure of liver viscoelastography using magnetic resonance Imaging (MRI)

    Time frame: Within 6 weeks of liver echography

  2. Liver viscoelastography determined by QUS

    Measure of liver viscoelastography using quantitative ultrasound (QUS).

    Time frame: Within 6 weeks of liver echography

  3. Detection of focal HCC lesions

    Detection of focal HCC lesions using quantitative ultrasound (QUS).

    Time frame: Within 6 weeks of liver echography

07

Study locations

1 of 1 sites recruiting
  • Centre hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
    • Guy Cloutier, PhD · Contactguy.cloutier@umontreal.ca · 514-890-8000
    • Louise Allard, PhD · Contactlouise.allard@crchum.qc.ca · 514-890-8000
    • Marc Bilodeau, MD · Sub investigator
    • Hélène Castel, MD · Sub investigator
    • Jeanne-Marie Giard, MD · Sub investigator
    • Bich Nguyen, MD · Sub investigator
    • Marie-Pierre Sylvestre, PhD · Sub investigator
    • Elijah Van Houten, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided — plan undicided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Oct 2027, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 1, 2020
StartActual
Oct 5, 2020
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 22, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04409340
Collaborators
Siemens Corporation, Corporate Technology, Fonds de la Recherche en Santé du Québec, Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
Oct 5, 2020
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 22, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Guy Cloutier, PhD
Contact
guy.cloutier@umontreal.ca
514-890-8000 ext. 24703
Louise Allard, PhD
Contact
louise.allard@crchum.qc.ca
514-890-8000 ext. 24705
Guy Cloutier, PhD
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)
An Tang, MD, MSc
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion